Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Capital Leases (2019 - 2022)

Agios Pharmaceuticals (AGIO) has disclosed Capital Leases for 4 consecutive years, with $276000.0 as the latest value for Q1 2022.

  • For Q1 2022, Capital Leases rose 11.29% year-over-year to $276000.0; the TTM value through Mar 2022 reached $276000.0, up 11.29%, while the annual FY2021 figure was $276000.0, 16.62% down from the prior year.
  • Capital Leases hit $276000.0 in Q1 2022 for Agios Pharmaceuticals, roughly flat from $276000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $673000.0 in Q4 2019 and bottomed at $167000.0 in Q2 2021.
  • Average Capital Leases over 4 years is $340428.6, with a median of $276000.0 recorded in 2021.
  • Year-over-year, Capital Leases plummeted 50.82% in 2020 and then increased 11.29% in 2022.
  • Agios Pharmaceuticals' Capital Leases stood at $673000.0 in 2019, then tumbled by 50.82% to $331000.0 in 2020, then dropped by 16.62% to $276000.0 in 2021, then changed by 0.0% to $276000.0 in 2022.
  • According to Business Quant data, Capital Leases over the past three periods came in at $276000.0, $276000.0, and $167000.0 for Q1 2022, Q4 2021, and Q2 2021 respectively.